Locations
Mercer Island, WA, USA · Seattle, WA, USA · University of Washington, Seattle, WA, USA
industry
Biotechnology
Size
11-50 employees
Stage
Series B
founded in
2019
Altpep develops early disease-modifying treatments and detection tools for amyloid diseases by targeting one of the earliest molecular triggers – toxic soluble oligomers. These oligomers are associated with many diseases, including neurodegenerative diseases and Type 2 diabetes. Decades of scientific research by the Daggett Research Group culminated in the discovery of a novel protein structure, alpha-sheet, the foundation of our innovative approach. Our lead program aims to identify Alzheimer’s disease long before symptoms occur and then neutralize the toxic soluble oligomers associated with the disease.
Something looks off?